ReviewExpert review of anti-infective therapy2019
Oxfendazole: a promising agent for the treatment and control of helminth infections in humans.
Review in Expert review of anti-infective therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 47 citations in OpenAlex.
- Pharmacokinetics, safety, and tolerability of an oxfendazole tablet formulation: a phase 1, randomized, placebo-controlled trial in healthy African volunteers.Antimicrobial agents and chemotherapy · 2026Trial
- Repurposing Oxfendazole for Onchocerciasis: Population Pharmacokinetics of a Tablet Formulation in Healthy African Adults.CPT: pharmacometrics & systems pharmacology · 2026Trial
- Pharmacokinetics of fenbendazole and its bioactive metabolite oxfendazole in northern bobwhite administered an anthelmintic feed.International journal for parasitology. Drugs and drug resistance · 2026Article
- Efficacy of oxfendazole treatment against infective larvae of Litomosoides sigmodontis.PLoS neglected tropical diseases · 2026Article
- Evaluation of Different Benzimidazole Formulations Against Sheep Naturally Infected withVeterinary sciences · 2026Article
- Pharmacokinetic barriers to oxfendazole flukicidal efficacy.PloS one · 2026Article
- Onchocerciasis overview: pathogenesis, clinical spectrum, and therapeutic challenges of a neglected tropical disease.Frontiers in parasitology · 2026Review
- In vitro screening of the open-access Pandemic Response Box reveals ESI-09 as a compound with activity against Echinococcus multilocularis.International journal for parasitology. Drugs and drug resistance · 2025Article
- Synergistic interaction between praziquantel and oxfendazole or fenbendazole in a murine cysticercosis model.Antimicrobial agents and chemotherapy · 2025Article
- Understanding the pathogenic mechanisms and therapeutic effects in neurocysticercosis.Brain pathology (Zurich, Switzerland) · 2024Article
- In Vitro Lethality of Fenbendazole to the EyewormAnimals : an open access journal from MDPI · 2024Article
- Combinations of the azaquinazoline anti-Frontiers in microbiology · 2024Article
- The pipeline for drugs for control and elimination of neglected tropical diseases: 1. Anti-infective drugs for regulatory registration.Parasites & vectors · 2023Review
- The efficacy of the benzimidazoles oxfendazole and flubendazole againstFrontiers in microbiology · 2023Article
- Effects of Ferula asafetida, closantel, albendazole, oxfendazole, and ivermectin against Haemonchus contortus in goats and sheep.Tropical animal health and production · 2022Article
- Population Pharmacokinetic-Pharmacodynamic Model of Oxfendazole in Healthy Adults in a Multiple Ascending Dose and Food Effect Study and Target Attainment Analysis.Antimicrobial agents and chemotherapy · 2022Article
- Human filariasis-contributions of the Litomosoides sigmodontis and Acanthocheilonema viteae animal model.Parasitology research · 2021Review
- Soybean (International journal of molecular sciences · 2021Article
- Population Pharmacokinetic Model of Oxfendazole and Metabolites in Healthy Adults following Single Ascending Doses.Antimicrobial agents and chemotherapy · 2021Article
- Drugs that target early stages of Onchocerca volvulus: A revisited means to facilitate the elimination goals for onchocerciasis.PLoS neglected tropical diseases · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 3 countries.
Funding
Abstract
introductionOxfendazole (methyl [5-(phenylsulphinyl)-1H benzimidazole-2-yl] carbamate) has a particularly long metabolic half-life in ruminants, and its metabolite fenbendazole also has anthelminthic action. A very limited number of drugs are available for the treatment of some zoonotic helminth infections, such as neurocysticercosis and echinococcosis. More recent work has expanded oxfendazole's nonclinical safety profile and demonstrated its safety and bioavailability in healthy human volunteers, thus advancing the possibility of a new and greatly needed option for antiparasitic treatment of geohelminths and tissue parasites. Areas covered: The present article reviews evidence supporting the safety and efficacy of oxfendazole against both gut and tissue dwelling helminths in animals, as well as more recent safety and pharmacokinetic data supporting its potential for use in human parasitoses. Expert commentary: The pharmacokinetics, safety, and wide spectrum of efficacy of oxfendazole are consistently demonstrated in intestinal helminth infections of animals as well as in tissue dwelling larval cestode and trematode infections in diverse animal species. Now supported by first-in-human safety and pharmacokinetic data, oxfendazole becomes a promising alternative to the limited portfolio of antiparasitic drugs available to treat helminthic diseases of humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.